Australian researchers have developed a new targeted therapy for myelofibrosis, a rare and severe blood cancer that blocks healthy blood cell formation. Using immunotherapy, they identified two precise targets to attack abnormal cells causing the disease. This breakthrough could transform treatment, offering more effective, long-term solutions beyond symptom control.